AVI BioPharma 2005 News Archive

November

AVI BioPharma Strengthens Scientific Advisory Board to Address Infectious Disease and Avian Influenza November 17, 2005, Portland, Oregon
AVI BioPharma to Present at 28th Annual Westergaard SmallCap Conference November 16, 2005, Portland, Oregon
AVI BioPharma Announces $22.6 Million Direct Equity Placement November 14, 2005, Portland, Oregon
Third Quarter 2005 Financial Results Conference Call Transcript November 7, 2005, Portland, Oregon
AVI BioPharma Reports Third Quarter Financial Results November 4, 2005, Portland, Oregon
AVI BioPharma to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference November 3, 2005, Portland, Oregon

October

AVI BioPharma Announces 2005 Third Quarter Financial Results Conference Call October 27, 2005, Portland, Oregon
Results From AVI BioPharma’s Antiviral Program Published in Two Virology Journals October 25, 2005, Portland, Oregon
AVI BioPharma Provides Update on Influenza Drug Development Program October 21, 2005, Portland, Oregon
AVI BioPharma Announces Presentation of Data at Transcatheter Cardiovascular Therapeutics Conference October 19, 2005, Portland, Oregon
AVI BioPharma Updates Results From Department of Defense Funded Collaborative Programs October 14, 2005, Portland, Oregon
AVI BioPharma Included in Initial Defense Funding Allocation October 3, 2005, Portland, Oregon

September

AVI BioPharma Introduces ESPRIT With Initial Application in Muscular Dystrophy September 29, 2005, Portland, Oregon
AVI BioPharma Initiates Hepatitis C Clinical Trial September 28, 2005, Portland, Oregon
AVI BioPharma Initiates Phase II Cardiovascular Clinical Study in Europe September 20, 2005, Portland, Oregon

August

Second Quarter 2005 Financial Results Conference Call Transcript August 9, 2005, Portland, Oregon
AVI BioPharma Reports Second Quarter Financial Results August 8, 2005, Portland, Oregon
AVI BioPharma Announces 2005 Second Quarter Financial Results Conference Call August 1, 2005, Portland, Oregon

July

AVI BioPharma Reports Continued Success in Preclinical Antiviral Efforts July 26, 2005, Portland, Oregon
AVI BioPharma Announces Publication of SARS NeuGene Antisense Studies in the Journal of Virology July 19, 2005, Portland, Oregon

June

AVI BioPharma Submits IND for NeuGene Antisense Drug Targeting Hepatitis C Virus June 30, 2005, Portland, Oregon
AVI BioPharma and Collaborators Announce Positive Results With NeuGene Antisense Drugs at American Society for Virology Annual Meeting June 20, 2005, Portland, Oregon
AVI BioPharma Will Present at Rodman & Renshaw Techvest 2nd Annual Security and Connectivity Investor Conference June 14, 2005, Portland, Oregon
Written Testimony of Alan P. Timmins President and Chief Operating Officer AVI Biopharma, Inc. - Crossing The Valley Of Death: Bringing Promising Medical Countermeasures To Bioshield June 9, 2005, Portland, Oregon
AVI BioPharma to Testify Before Congressional Committee on Bioterrorism Research and Development June 9, 2005, Portland, Oregon
AVI BioPharma Announces Positive Results With Neugene Antisense Drugs at the Endocrine Society Annual Meeting June 6, 2005, Portland, Oregon

May

First Quarter 2005 Financial Results Conference Call Transcript May 10, 2005, Portland, Oregon
Avi Biopharma Announces First Quarter Financial Results May 9, 2005, Portland, Oregon
AVI BioPharma Announces 2005 First Quarter Financial Results Conference Call May 2, 2005, Portland, Oregon

April

AVI BioPharma Will Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference April 28, 2005, Portland, Oregon
AVI BioPharma Presents Positive Results With NeuGene Antisense Drugs At the American Association for Cancer Research Meeting April 20, 2005, Portland, Oregon
AVI BioPharma Announces Positive Results in NeuGene® Antisense Studies With Collaborators Targeting Emerging Viral Diseases April 12, 2005, Portland, Oregon

March

AVI BioPharma Announces Publication of West Nile and Dengue Virus NeuGene Antisense Studies in the Journal of Virology March 30, 2005, Portland, Oregon
Fourth Quarter 2004 Financial Results Conference Call Transcript March 10, 2005, Portland, Oregon
AVI BioPharma Announces 2004 Fourth Quarter and Full Year Financial Results March 8, 2005, Portland, Oregon
AVI BioPharma Announces New Board Member Appointments March 8, 2005, Portland, Oregon
AVI BioPharma Announces 2004 Fourth Quarter and Year End Financial Results Conference Call March 1, 2005, Portland, Oregon

January

AVI BioPharma Updates Progress on Infectious Disease Program Using NeuGene Antisense Drugs For RNA Viruses January 25, 2005, Portland, Oregon
AVI BioPharma Announces $24 Million Direct Equity Placement January 19, 2005, Portland, Oregon
AVI BioPharma Receives Key U.S. Patents Covering Preservation and Expansion of Stem Cells Using Third-Generation NeuGene Antisense January 19, 2005, Portland, Oregon
AVI BioPharma Appoints Vice President of Cardiology January 18, 2005, Portland, Oregon

About AVI BioPharma

Technology

Communication